Literature DB >> 3772175

Granulopoiesis in long-term culture by marrow from mice with busulfan-induced chronic latent aplasia.

R L Boyd, J Caro, K G Halka, A J Erslev.   

Abstract

Mice given high-dose busulfan therapy develop a chronic latent marrow aplasia characterized by normal peripheral blood neutrophil numbers, hematocrits and marrow cellularity but reduced numbers of pluripotent hemopoietic stem cells (CFU-s) and granulocyte-monocyte progenitor cells (CFU-gm). To study the pathogenesis of this lesion, bone marrow was propagated in long-term marrow cultures (LTMC). Small amounts of normal marrow readily established and sustained long-term granulopoiesis in vitro. In contrast, inocula of marrow from busulfan-treated animals containing three to five times as many stem and progenitor cells failed to establish long-term granulopoiesis in vitro. These results suggest that high-dose busulfan therapy produces a qualitative defect in either the hemopoietic stem cells, the stromal-forming elements, or both, rendering them incapable of establishing long-term granulopoiesis in vitro. Furthermore, mixing experiments employing normal and busulfan-damaged marrow demonstrate that this qualitative defect is not due to the emergence of a suppressor cell population. LTMC can show types of marrow damage not detectable by other techniques currently available and represent a powerful tool for studying latent bone marrow failure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3772175     DOI: 10.1002/stem.5530040507

Source DB:  PubMed          Journal:  Int J Cell Cloning        ISSN: 0737-1454


  2 in total

Review 1.  Animal models for acquired bone marrow failure syndromes.

Authors:  Jichun Chen
Journal:  Clin Med Res       Date:  2005-05

2.  Human B cell development and antibody production in humanized NOD/SCID/IL-2Rγ(null) (NSG) mice conditioned by busulfan.

Authors:  Bongkum Choi; Eunyoung Chun; Miyoung Kim; Seong-Tae Kim; Keejung Yoon; Ki-Young Lee; Sung Joo Kim
Journal:  J Clin Immunol       Date:  2010-10-28       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.